ARTICLE | Company News
Eisai, Drugs for Neglected Diseases initiative deal
October 5, 2009 7:00 AM UTC
DNDi received a license to develop Eisai's E1224 to treat Chagas disease. The prodrug of the antifungal ravuconazole is in preclinical testing. Eisai will supply the compound and provide scientific e...